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Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against
ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained
self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used
conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147
women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of
birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their
matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1
year was 0.85 (95 percent confidence interval, 0.53–1.36). The risk decreased by 5% (1–9%) with each year of use (P for
trend¼0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35–1.09). These data support the hypothesis
that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2.
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Women who carry deleterious mutations of the genes BRCA1 or
BRCA2 are at increased risk of developing ovarian cancer
(Struewing et al, 1997; Ford et al, 1998, Antoniou et al, 2003).
Oral contraceptive use is associated with reduced ovarian cancer
risk in the general population (Whittemore et al, 1992; La Vecchia
and Franceschi, 1999). It is important to know if a similar
association holds for mutation carriers. Previous investigations
have addressed this question with conflicting results (Narod et al,
1998, 2001a; Modan et al, 2001; McGuire et al, 2004). Resolution of
this issue is important because oral contraceptive use at early ages
may increase the risk of breast cancer in mutation carriers (Ursin
et al, 1997; Narod et al, 2002).
We report the results of an analysis of ovarian cancer risk in
relation to oral contraceptive use among 451 carriers of BRCA1 or
BRCA2 mutations, comprising 147 women with ovarian cancer
(cases) and 304 women without ovarian cancer (controls) who
were identified in one of five family registries in the US, Canada,
England and Australia.
METHODS
Subjects
We used five registry sources to ascertain female carriers with
germline mutations of BRCA1 or BRCA2, and classified them as
cases (those diagnosed with primary invasive cancer of the ovarian
epithelium, confirmed by pathology report or death certificate) or
controls. The first source (eight cases and 12 controls) was families
enrolled with the United Kingdom Consortium for Clinical Cancer
Research (UKCCCR) Ovarian Cancer Register. Eligible families
were those containing at least two first- or second-degree relatives
confirmed with invasive epithelial ovarian cancer. The second
source (27 cases and 51 controls) was Australian families
registered with the Kathleen Cuningham Foundation Consortium
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2000; http://www.kconfab.org). Eligible families contained two
living women with breast or ovarian cancer, or one living affected
plus one female carrier. The third source (54 cases and 24 controls)
was families enrolled in the Gilda Radner Familial Ovarian Cancer
Registry at the Roswell Park Cancer Institute in Buffalo, NY, USA.
Eligible families contained two or more relatives with a confirmed
diagnosis of cancer of the ovary, peritoneum or fallopian tubes.
The fourth source (nine cases and 24 controls) was families
identified by the Risk Assessment Program at the Fox Chase
Cancer Center in Philadelphia, PA, USA. The fifth source (49 cases
and 193 controls) was families from the US, Canada and Australia
enrolled in the Breast Cancer Family Registry (Breast CFR) (John
et al, 2004).
We included in the analysis women who were found by genetic
testing to carry a germline mutation in BRCA1 or BRCA2 that was
predicted to adversely affect protein function (National Human
Genome Research Project, 2002) who provided information
concerning their reproductive characteristics and oral contra-
ceptive use in a structured questionnaire, and who had not
participated as a study subject in any other study of oral
contraceptive use and ovarian cancer risk.
Mutation analysis
In the UKCCCR Ovarian Cancer Register and the GRFOCR
Registry, one affected member from each family (hereafter called
the index case) was tested for germline mutations in BRCA1 and
BRCA2 by a combination of the protein truncation test (PTT) and
single-strand conformation analysis/heteroduplex analysis (SSCP/
HA), as described previously (Gayther et al, 1999). Direct sequence
analysis was used to characterise the nucleotide alteration
associated with PTT or SSCP/HA variants. When a mutation was
identified in an index case, other family members were tested for
that mutation by direct sequencing. Women registered with the
Fox Chase Cancer Center were tested for mutations using the
enzymatic mutation detection assay (Del Tito et al, 1998).
Mutation testing for members of families enrolled in kConFab
(Scott et al, 2003) and the Breast CFR (John et al, 2004) was
undertaken in several different diagnostic laboratories using
different strategies including HA, PTT, chemical cleavage of
mismatch, allele-specific oligonucleotide hybridisation and direct
sequencing.
Study protocol
Participants provided data on their histories of childbearing,
oophorectomy and use of oral contraceptives. The women reported
the ages when they started and stopped taking oral contraceptives
and their total durations of use. No information from surrogate
interviews was included in the analysis.
Statistical analysis
To each carrier we assigned a reference age, defined as her age at
diagnosis if she was a case, or as her age at the earlier of
oophorectomy or interview if she was a control. We matched each
case to one or more controls. Controls were matched to the case on
year of birth (within 3 years), country of residence (Australia,
Canada, UK, US) and gene (BRCA1, BRCA2). In addition, the
reference ages of controls must have exceeded those of their
matched case. Within each matched set, we considered childbirth
and oral contraceptive use only prior to the case’s reference age.
We performed a matched case–control analysis using conditional
logistic regression (Breslow and Day, 1980), with parity (0, 1 or 2,
3þ live births) included in the regression models. Since we are
testing the null hypothesis of no association between ovarian
cancer risk and oral contraceptive use against the alternative
hypothesis of reduced risk associated with oral contraceptive use,
we report one-tailed P-values.
RESULTS
We were able to find at least one matched control for 114 cases
with BRCA1 mutations (the mean number of controls per case was
2.0, with range 1–3) and for 33 cases with BRCA2 mutations (mean
number of controls per case was 2.4, with range 1–3). Table 1
shows the distributions of matched case–control sets according to
age at diagnosis, year of birth and country of residence of the
cases, by gene. Most cases were diagnosed between the ages of 40
and 60 years, and most were born after 1930. Cases (and therefore
controls) were more likely to carry mutations of BRCA1 than
BRCA2 by a factor of more than three.
Table 2 shows the distributions of participants according to
reproductive characteristics and oral contraceptive use, by gene
and case–control status. Compared to controls, cases were less
likely to use oral contraceptives and had used them for fewer years.
Overall, 31% of ovarian cancer patients and 36% of control women
carried one of the two common founder mutations of BRCA1 (185
del AG or 5382 ins C) or the single common founder mutation of
BRCA2 (6174 del T).
Table 3 shows ovarian cancer odds-ratios in relation to oral
contraceptive use. The odds-ratio associated with use for at least 1
year, compared to use for less than 1 year or nonuse, was 0.85
(95% confidence interval 0.53–1.4). Also shown are odds-ratios in
relation to duration of oral contraceptive use. The odds-ratio
among carriers who had used oral contraceptives for 6 or more
years compared to those who had used them for less than 1 year
was 0.62 (95% confidence interval 0.35–1.1). The data show a
trend of decreasing risk with increasing duration of use, with an
overall 5% (95% confidence interval 1–9%) reduction in risk per
year of use (one-tailed P¼0.01).
When restricted to BRCA1 mutation carriers, estimates of
associations with oral contraceptives use were similar to those
shown in Table 3. Estimates based on BRCA2 mutation carriers
alone were imprecise, and were not statistically different from
those for BRCA1 mutation carriers.
Table 1 Distribution of matched ovarian cancer case–control sets
a,
according to case’s age at diagnosis, year of birth and country of residence,
by gene
BRCA1 BRCA2 Total
N (%) N (%) N (%)
Case’s age at dx (%)
o40 18 (16) 3 (9) 21 (14)
40–49 55 (48) 12 (36) 67 (46)
50–59 29 (25) 10 (31) 39 (27)
60+ 12 (11) 8 (24) 20 (13)
Case’s year of birth (%)
o1930 12 (11) 6 (18) 18 (12)
1930–1944 44 (39) 15 (46) 59 (40)
1945+ 58 (50) 12 (36) 70 (48)
Case’s country of residence
Australia 29 (25) 4 (12) 33 (23)
Canada 2 (2) 1 (3) 3 (2)
UK 8 (7) 0 (0) 8 (5)
US 75 (66) 28 (85) 103 (70)
Total no. of matched sets 114 33 147
aControls had intact ovaries at the age when the case was diagnosed, and were
matched to cases on gene (BRCA1 or BRCA2), year of birth (73 years) and country
of residence (Australia, Canada, UK, USA).
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Among women who carry mutations of BRCA1 or BRCA2, we
found reduced risk associated with use of oral contraceptives and
evidence for increasing risk reduction with increasing duration of
use. The reduction in risk of 14% among ever users and 38%
among long-term users are consistent with, but somewhat weaker
than, reductions observed in the general population. In a pooled
analysis of six population-based case–control studies of oral
contraceptives and the risk of ovarian cancer in the US, the risk
reduction associated with ever use was 34%, and that associated
with 6 or more years of use was 70% (Whittemore et al, 1992).
Other studies have produced conflicting results on the relation-
ship between ovarian cancer risk and oral contraceptive use among
carriers of BRCA1 or BRCA2 mutations. Narod et al (1998, 2001a)
found risk reductions of magnitude similar to those seen here. The
risk reductions did not vary when the authors separated carriers
by type of mutation (BRCA1 vs BRCA2). In a population-based
case–control study of ovarian cancer among women in Northern
California, McGuire et al (2004) also found an inverse relationship
between oral contraceptive use and ovarian cancer risk when
comparing patients carrying a BRCA1 mutation with control
women from the general population. In contrast, in a similar
population-based case–control study of ovarian cancer among
women in Israel, Modan et al (2001) found no differences in oral
contraceptive use when comparing patients carrying one of the
three common BRCA1 or BRCA2 founder mutations with control
women from the general Israeli population. The discrepancies
between these results, if not due to chance or bias, could reflect
differences in the populations at risk, the specific types of
mutations studied, or study design (Modan and Wacholder,
2001; Narod et al, 2001b).
The present results, based on data that have not been reported in
any previous studies of oral contraceptive use and ovarian cancer,
support previous findings of Narod et al (1998, 2001a). Our study
and those of Narod et al share some limitations. First, they
included data only from living affected carriers because of the
difficulty of obtaining accurate histories from relatives of deceased
patients. These living patients were prevalent cases who reported
their prediagnostic oral contraceptive histories some time after
their cancer diagnoses. If oral contraceptive use is associated with
an altered mortality in women with ovarian cancer, then this
selection strategy may result in a biased odds-ratio estimate.
Second, most study subjects were members of families with
multiple cases of breast and ovarian cancer, and therefore the
mutations in the women we have studied may have been those that
cause a higher risk of these cancers. Odds-ratios for oral
contraceptive uses in these carriers may not pertain to the general
population of carriers. Third, some of the unaffected carriers were
relatives of ovarian cancer patients. While this design limits
potential confounding by ethnicity, a disadvantage is that
correlation among sisters in oral contraceptive use could distort
both the magnitude of the association and the lengths of
confidence intervals. Yet we found only modest correlation
between sisters in duration of oral contraceptive use. In addition,
our inclusion of control carriers who had undergone prophylactic
oophorectomy could overestimate the protection afforded by oral
contraceptive use, if these carriers were more likely to use oral
contraceptives than other carriers. However, we found no
difference in the prevalence of oral contraceptive use between
carriers with and without prophylactic oophorectomy.
The studies by Modan et al (2001) and McGuire et al (2004)
avoided these limitations by including only incident cases of
ovarian cancer in mutation carriers and unrelated controls.
Prevalence of oral contraceptive use among carrier cases was
compared to that in control women from the general population.
Inferences based on such a comparison are valid only if oral
contraceptive use is similar among carriers and noncarriers in the
general population. The null findings of Modan et al (2001) may
have occurred because the oral contraceptive use of carrier cases
was compared to that of controls who were older than they were.
This difference occurred because controls were age-matched to all
cases, whereas the carrier cases were younger than the noncarrier
cases, and the analytic comparisons were stratified only in broad
10-year age categories. Thus, the comparison controls were
born earlier than the carrier cases, and had less opportunity
for long-term exposure to oral contraceptives, which did not
become widespread until after 1960. This problem was mitigated
in the report of McGuire et al (2004) by the more recent birth
years of all subjects, and by finer age stratification in the
analysis.
Table 2 Characteristics of ovarian cancer cases and control women, by gene
BRCA1 BRCA2 Total
Cases Controls Cases Controls Cases Controls
No. 114 225 33 79 147 304
Mean no. live births 2.5 2.5 2.6 2.5 2.5 2.5
Mean age of (years) first birth among parous 23.5 24.6 24 24.5 23.6 24.6
Ever used oral contraceptives (%) 53 63 54 58 53 62
Mean years of oral contraceptive use among users 3.0 4.7 3.1 4.3 3.0 4.6
Prophylactic bilateral oophorectomy (%) — 15 — 6 — 12
Carrier of Ashkenazi founder mutation
a (%) 32 39 27 29 31 36
aMutations 185 del AG, 5382 ins C or 6174 del T.
Table 3 Ovarian cancer risk according to oral contraceptive use among
carriers of BRCA1 or BRCA2 mutations
Cases
(N¼147)
No. (%)
Controls
(N¼304)
No. (%) OR
a CI
b
Any use
c
No 69 (46.9) 116 (38.2) 1.0 —
Yes 78 (53.1) 188 (61.8) 0.85 0.53–1.4
Years of use
o1 69 (46.9) 116 (38.2) 1.0 —
1–2 31 (21.1) 40 (13.2) 1.5 0.82–2.9
3–5 14 (9.5) 44 (14.4) 0.69 0.33–1.4
6+ 33 (22.5) 104 (34.2) 0.62 0.35–1.1
Trend per year of use among
users
0.95 0.91–0.99
aOR¼odds ratio, adjusted for study centre, parity and age.
bCI¼95% confidence
interval.
cFor at least 1 year.
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with long-term oral contraceptive use among carriers of BRCA1 or
BRCA2 mutations. Both the reduced incidence among ever-users
and the trend of decreasing risk with increasing duration of use are
consistent with a protective effect for oral contraceptives in these
women. If such protection exists, the benefits of oral contraceptive
use must be weighed against its possible adverse effects on breast
cancer risk. Although there are data to suggest that oral contra-
ceptive use is associated with a small increased breast cancer risk
in carriers of BRCA1 (but not BRCA2) mutations (Narod et al
2002), this effect was being driven by use prior to the mid 1970s. A
more recent population-based study has found no evidence for an
increased risk in mutation carriers associated with use of current
formulations of oral contraceptives, and evidence that current
formulations may even be protective for BRCA1 mutation carriers
(Milne et al, 2004). Therefore, oral contraceptive use in women
with BRCA1 mutations should be considered in light of any
planned prophylactic surgery. The current data suggest that
women with intact ovaries who undergo prophylactic mastectomy
would be good candidates for oral contraceptives. Further data are
needed to advise those who undergo prophylactic oophorectomy
but not mastectomy.
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